About: Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
Creator	Cimmino, Giovanni Cirillo, Plinio Conte, Stefano Morello, Andrea Pellegrino, Grazia »more»
source	Medline; PMC
abstract	Platelets aggregation leading to thrombosis plays a pivotal role in the pathophysiology of acute coronary syndrome (ACS) and of stent thrombosis. Antiplatelet therapy with aspirin plus an ADP-receptor inhibitor (ticagrerol, prasugrel or clopidogrel) is recommended to reduce the risk of other platelet-mediated events. Clopidogrel is recommended in patients with Chronic Coronary Syndromes (CCS) or in ACS patients at high bleeding risk. Unfortunately, up to 30% of patients are non-responders to clopidogrel and show residual high platelet reactivity (HPR). Colchicine (COLC) is a drug with cardiovascular effects. We have demonstrated that COLC might exert protective cardiovascular effects by interfering with cytoskeleton rearrangement, a phenomenon involved in platelet aggregation. Here, we investigate in vitro the effects of colchicine on platelet aggregation of patients on DAPT with clopidogrel. Platelets obtained from 35 CCS patients on therapy with clopidogrel were pre-incubated with COLC 10 µM before being stimulated with ADP (20 µM), or TRAP (25 µM) at 0, 30, 60 and 90 min to measure max aggregation by LTA. Platelets not COLC-preincubated served as controls. Seven patients were pre-selected as clopidogrel non-responders. COLC significantly reduced TRAP-induced platelet aggregation in clopidogrel responders and non-responders. Interestingly, COLC inhibited ADP-induced platelet aggregation in clopidogrel non-responders in which ADP still caused activation despite DAPT. We demonstrate that COLC inhibits platelet aggregation in clopidogrel non-responders with HPR despite DAPT with this ADP receptor-inhibitor. Further in vivo studies should be designed to evaluate the opportunity to prescribe colchicine after ACS/CCS to overcome the clopidogrel limitations in the DAPT therapy.
has issue date	2020-04-25(xsd:dateTime)
bibo:doi	10.1007/s11239-020-02121-8
bibo:pmid	32335777
has license	no-cc
sha1sum (hex)	b5b0e065f02dbf9847b8817bf210095ab9f1053a
schema:url	https://doi.org/10.1007/s11239-020-02121-8
resource representing a document's title	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
has PubMed Central identifier	PMC7183388
has PubMed identifier	32335777
schema:publication	J Thromb Thrombolysis
resource representing a document's body	covid:b5b0e065f02dbf9847b8817bf210095ab9f1053a#body_text
is schema:about of	named entity 'inhibits' named entity 'aggregation' named entity 'max' named entity 'aspirin' named entity 'evaluate' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software